Skip to main content

Market Overview

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)

130.62 +4.14 (3.27%)

Analyst Ratings

DateResearch FirmActionCurrentPT
5/04/21BarclaysMaintainsOverweight190.0
2/04/21BarclaysMaintainsOverweight198.0
2/04/21Roth CapitalMaintainsBuy200.0
2/04/21HC Wainwright & Co.MaintainsBuy310.0
10/21/20Craig-HallumMaintainsBuy195.0
9/29/20Roth CapitalReiteratesBuy195.0
8/04/20BarclaysMaintainsOverweight145.0
4/08/20HC Wainwright & Co.MaintainsBuy229.0
3/24/20Argus ResearchDowngradesHold
3/10/20Guggenheim SecuritiesInitiates Coverage OnNeutral

Data powered by Benzinga Pro Calendars - Start your FREE TRIAL today!

Sign up to receive Benzinga's Daily Ratings Newsletter